# US 2025/0115548 A1 · Compounds as soluble epoxide hydrolase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0115548 A1
- Document ID: US20250115548A1
- Status: Published application
- Kind: A1
- Application number: 18/915,070
- Filed: 2024-10-14
- Published: 2025-04-10
- Earliest claimed: 2021-03-24
- Assignees: Universitat De Barcelona
- Applicants: Universitat De Barcelona
- Inventors: Sandra CODONY I GISBERT; Cristian Gaspar GRIÑAN FERRE; Mercè PALLÀS LLIBERIA; Santiago VÁZQUEZ CRUZ; Yumin OH
- Web page: https://patentgrep.com/patent/US20250115548A1

## CPC

- C07C 275/26: having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 211/58: attached in position 4
- C07D 211/60: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/96: Sulfur atom
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07C 2601/14: The ring being saturated
- C07C 2603/78: containing seven-membered rings
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A compound of formula (I)
or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
G1 represents a nitrogen atom or a —CH— group;
when G1 is nitrogen atom group, R1 is selected from
a) carbonyl containing groups selected from the group consisting of a1) linear or branched C3-C6 acyl or C3-C6 cycloalkyl-C(═O), all of them optionally substituted by 1 substituent selected from the group consisting of halogen atoms, cyano (C≡N), trifluoromethoxy (OCF3), and C1-C6 alkoxy, a2) trifluoroacetyl, 3,3,3-trifluoropropionyl, tetrahydropyrancarbonyl, oxetanecarbonyl or (tetrahydro-2H-thiopyran)carbonyl, and a3) C6-C14-arylcarbonyl or C4-C14-heteroarylcarbonyl wherein the heteroaryl group has 5 to 14 members and 1 to 3 heteroatoms selected from the group consisting of N, O and S in the ring system, all of them optionally substituted by 1 to 4 substituents selected from the group consisting of halogen atoms, cyano (C≡N), trifluoromethyl (CF3), trifluoromethoxy (OCF3), pentafluorosulfanyl (SF5), sulfonyl (SO3H), carboxylic group (COOH), ester group (COOR4), amino (NH2), mono-C1-C6 alkylamino, di-C1-C6 alkylamino, hydroxyl, C1-C6 alkoxy and C1-C6 alkyl;
b) phenyl which may be optionally substituted by 1 to 4 substituents selected from the group consisting of halogen atoms, C1-C6 acyl, cyano (C≡N), trifluoromethyl (CF3), trifluoromethoxy (OCF3), pentafluorosulfanyl (SF5), sulfonyl (S03H), fluorosulfonyl (SO2F), carboxylic group (COOH), ester group (COOR4), amino (NH2), mono-C1-C6 alkylamino, di-C1-C6 alkylamino, hydroxyl, C1-C6 alkoxy, C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 alkoxycarbonylmethyl, and
c) sulfonyl containing groups selected from the group consisting of linear or branched C1-C6 alkylsulfonyl, C3-C6 cycloalkylsulfonyl, and C6-C10 arylsulfonyl optionally substituted by 1 to 2 substituents selected from the group consisting of halogen atoms, nitro (NO2), cyano (C≡N), trifluoromethyl (CF3), trifluoromethoxy (OCF3), pentafluorosulfanyl (SF5), sulfonyl (SO3H), carboxylic group (COOH), ester group (COOR4), amino (NH2), mono-C1-C6 alkylamino, di-C1-C6 alkylamino, hydroxyl, C1-C6 alkoxy, C1-C6 alkyl and C1-C6 alkoxycarbonylmethyl;
when G1 is a —CH— group, R1 is a phenoxy which may be unsubstituted or substituted by 1 to 4 groups selected from COOH, COOR4, CONH2, CN, fluor, chloro, trifluoromethyl, cyclopropyl and OH;
R2 is an halogen atom;
R3 is selected from the group consisting of hydrogen and methoxy;
R4 is a radical selected from C1-C6 alkyl and C3-C6 cycloalkyl
and stereoisomers and pharmaceutically acceptable salts thereof.

### Claim 20 (depends on 19)

The compound according to claim 19 wherein G1 is N.

### Claim 21 (depends on 20)

The compound according to claim 20 wherein R1 is a carbonyl-containing group selected from the group consisting of a1) linear or branched C3-C6 acyl, C3-C6 cycloalkyl-C(═O), all of them optionally substituted by 1 substituent selected from the group consisting of halogen atoms, cyano (C≡N), trifluoromethoxy (OCF3), and C1-C6 alkoxy, a2) trifluoroacetyl, 3,3,3-trifluoropropionyl, tetrahydropyrancarbonyl, oxetanecarbonyl or (tetrahydro-2H-thiopyran)carbonyl and a3) C6-C14-arylcarbonyl or C4-C14-heteroarylcarbonyl wherein the heteroaryl group has 5 to 14 members and 1 to 3 heteroatoms selected from the group consisting of N, O and S in the ring system, all of them optionally substituted by 1 to 4 substituents selected from the group consisting of halogen atoms, cyano (C≡N), trifluoromethyl (CF3), trifluoromethoxy (OCF3), pentafluorosulfanyl (SF5), sulfonyl (SO3H), carboxylic group (COOH), ester group (COOR4), amino (NH2), mono-C1-C6 alkylamino, di-C1-C6 alkylamino, hydroxyl, C1-C6 alkoxy and C1-C6 alkyl.

### Claim 22 (depends on 21)

The compound according to claim 21 wherein R1 is selected from the group consisting of linear or branched C3-C6 acyl, C3-C6 cycloalkyl-C(═O) optionally substituted with a F atom or a cyano group, trifluoroacetyl, 3,3,3-trifluoropropionyl, tetrahydropyrancarbonyl, oxetancarbonyl, (tetrahydro-2H-thiopyran)carbonyl.

### Claim 23 (depends on 20)

The compound according to claim 20 wherein R1 is a phenyl which may be optionally substituted by 1 to 4 substituents selected from the group consisting of halogen atoms, C1-C6 acyl, cyano (C≡N), trifluoromethyl (CF3), trifluoromethoxy (OCF3), pentafluorosulfanyl (SF5), sulfonyl (SO3H), fluorosulfonyl (SO2F), carboxylic group (COOH), ester group (COOR4), amino (NH2), mono-C1-C6 alkylamino, di-C1-C6 alkylamino, hydroxyl, C1-C6 alkoxy, C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 alkoxycarbonylmethyl.

### Claim 24 (depends on 20)

The compound according to claim 20 wherein R1 is a sulfonyl containing group selected from the group consisting of linear or branched C1-C6 alkylsulfonyl, C3-C6 cycloalkylsulfonyl, and C6-C10 arylsulfonyl which may be optionally substituted by 1 to 2 substituents selected from the group consisting of halogen atoms, nitro (NO2), cyano (C≡N), trifluoromethyl (CF3), trifluoromethoxy (OCF3), pentafluorosulfanyl (SF5), sulfonyl (SO3H), carboxylic group (COOH), ester group (COOR4), amino (NH2), mono-C1-C6 alkylamino, di-C1-C6 alkylamino, hydroxyl, C1-C6 alkoxy, C1-C6 alkyl and C1-C6 alkoxycarbonylmethyl.

### Claim 25 (depends on 19)

The compound according to claim 19 wherein G1 is a —CH— group and R1 is a phenoxy which may be unsubstituted or substituted by 1 to 2 groups selected from COOH, COOR4, CONH2, CN, fluor, chloro, trifluoromethyl, cyclopropyl and OH.

### Claim 26 (depends on 19)

The compound according to claim 19 wherein R2 is a chlorine or a fluorine atom, preferably it is a fluorine atom when G1 is nitrogen and it is a chlorine atom when G1 is CH.

### Claim 27 (depends on 19)

The compound according to claim 19 wherein each R3 is a hydrogen atom.

### Claim 28 (depends on 19)

The compound according to claim 19, which is selected from the group consisting of:
i. 4-[((1r,4r)-4-(3-(9-fluoro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)cyclohexyl)oxy]benzoic acid,
ii. 4-[((1r,4r)-4-(3-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)cyclohexyl)oxy]benzoic acid,
iii. 1-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(tetrahydro-2H-pyran-4-carbonyl)piperidin-4-yl)urea,
iv. 1-(9-fluoro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(tetrahydro-2H-pyran-4-carbonyl)piperidin-4-yl)urea,
v. 1-(9-fluoro-2,3-dimethoxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(tetrahydro-2H-pyran-4-carbonyl)piperidin-4-yl)urea,
vi. 1-(9-chloro-2,3-dimethoxy-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(tetrahydro-2H-pyran-4-carbonyl)piperidin-4-yl)urea,
vii. 1-(9-fluoro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(cyclopropanecarbonyl)piperidin-4-yl)urea,
viii. 1-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(cyclopropanecarbonyl)piperidin-4-yl)urea,
ix. 1-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(1-fluorocyclopropane-1-carbonyl)piperidin-4-yl)urea,
x. 1-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)urea,
xi. 1-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-(isopropylsulfonyl)piperidin-4-yl)urea,
xii. 1-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)-3-(1-propionylpiperidin-4-yl)urea,
xiii. 4-(4-(3-(9-fluoro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)piperidin-1-yl)benzoic acid,
xiv. 4-(4-(3-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)piperidin-1-yl)benzoic acid,
xv. methyl 4-(4-(3-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)piperidine-1-carbonyl)benzoate, and
xvi. 4-(4-(3-(9-chloro-5,6,8,9,10,11-hexahydro-7H-5,9:7,11-dimethanobenzo[9]annulen-7-yl)ureido)piperidine-1-carbonyl)benzoic acid.

### Claim 29 (depends on 1)

A pharmaceutical or veterinary composition comprising a therapeutically effective amount of a compound as defined in claim 1.

### Claim 30 (depends on 19)

A method of prevention or treatment of a disease or disorder susceptible of improvement by inhibition of soluble epoxide hydrolase by administration to a patient in need thereof a compound as defined in claim 19.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the disease or disorder is selected from the group consisting of hypertension, atherosclerosis, pulmonary diseases such as chronic obstructive pulmonary disorder, asthma, sarcoidosis and cystic fibrosis, kidney diseases such as acute kidney injury, diabetic nephrology, chronic kidney diseases, hypertension-mediated kidney disorders and high fat diet-mediated renal injury, stroke, pain, neuropathic pain, inflammation, pancreatitis in particular acute pancreatitis, immunological disorders, neurodevelopmental disorders such as schizophrenia and autism spectrum disorder, eye diseases in particular diabetic keratopathy, wet age-related macular degeneration and retinopathy such as premature retinopathy and diabetic retinopathy, cancer, obesity, including obesity-induced colonic inflammation, diabetes, metabolic syndrome, preeclampsia, anorexia nervosa, depression, male sexual dysfunction such as erectile dysfunction, wound healing, NSAID-induced ulcers, emphysema, scrapie, Parkinson's disease, arthritis, arrhythmia, cardiac fibrosis, Alzheimer's disease, Raynaud's syndrome, Niemann-Pick-type C disease, cardiomyopathy, vascular cognitive impairment, mild cognitive impairment, inflammatory bowel diseases, cirrhosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis, osteoporosis, chronic periodontitis, sepsis, seizure disorders such as epilepsy, dementia, edema such as cerebral edema, attention-deficit hyperactivity disorder, schizophrenia, drug dependency, social anxiety, colitis, amyotrophic lateral sclerosis, chemotherapy induced side effects, laminitis, inflammatory joint pain and synovitis, endothelial dysfunction, subarachnoid hemorrhage, including aneurysmal subarachnoid hemorrhage, traumatic brain injury, cerebral ischemia, diabetes-induced learning and memory impairment, cytokine storm, multiple sclerosis, and idiopathic pulmonary fibrosis.

### Claim 32 (depends on 19)

The compound of claim 19, wherein:
(i) R2 is a chlorine or a fluorine atom; preferably it is a fluorine atom when G1 is nitrogen and it is a chlorine atom when G1 is CH; or, alternatively,
(ii) R3 are both hydrogen atoms; or, alternatively,
(iii) R2 is a chlorine or a fluorine atom, preferably it is a fluorine atom when G1 is nitrogen and it is a chlorine atom when G1 is CH; and each R3 is a hydrogen atom.

### Claim 33 (depends on 29)

A method of prevention or treatment of a diseases or disorder susceptible of improvement by inhibition of soluble epoxide hydrolase by administration to a patient in need thereof of a composition according to claim 29.

### Claim 34 (depends on 22)

The compound according to claim 22 wherein R1 is selected from 2-methylbutanoyl, cyclopropyl-C(═O) and tetrahydropyrancarbonyl.

### Claim 35 (depends on 24)

The compound according to claim 24 wherein R1 is selected from the group consisting of C1-C6 alkylsulfonyl and C3-C6 cycloalkylsulfonyl.

### Claim 36 (depends on 32)

The compound of claim 32, wherein R2 is a fluorine atom when G1 is nitrogen and R2 is a chlorine atom when G1 is CH.

### Claim 37 (depends on 32)

The compound of claim 32, wherein R2 is a fluorine atom when G1 is nitrogen and R2 is a chlorine atom when G1 is CH, and each R3 is a hydrogen atom.
